Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

NCT07434180 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Cancer of Unknown Primary

Interventions

DRUG: 177Lu-FAP-2286

Sponsor

Peter MacCallum Cancer Centre, Australia

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]